Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORMP Oramed Pharmaceuticals

Closed 12-11 16:00:00 EST

3.04

+0.14

+4.66%

盘后3.00

-0.03-1.12%

19:54 EST

High3.14	Low2.86	Vol920.33K
Open2.90	D1 Closing2.90	Amplitude9.65%
Mkt Cap120.80M	Tradable Cap98.81M	Total Shares39.80M
T/O2.78M	T/O Rate2.83%	Tradable Shares32.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORMP","market":"US","secType":"STK","nameCN":"Oramed Pharmaceuticals","latestPrice":3.035,"timestamp":1765486800000,"preClose":2.9,"halted":0,"volume":920330,"hourTrading":{"tag":"盘后","latestPrice":3.0009,"preClose":3.035,"latestTime":"19:54 EST","volume":745,"amount":2263.272,"timestamp":1765500852460},"delay":0,"floatShares":32556743,"shares":39802455,"eps":1.026987,"marketStatus":"Closed","change":0.135,"latestTime":"12-11 16:00:00 EST","open":2.9,"high":3.1399,"low":2.86,"amount":2781128.476994,"amplitude":0.096517,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.026987,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765530000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.9,"postHourTrading":{"tag":"盘后","latestPrice":3.0009,"preClose":3.035,"latestTime":"19:54 EST","volume":745,"amount":2263.272,"timestamp":1765500852460},"volumeRatio":10.06232,"impliedVol":0.9154,"impliedVolPercentile":0.528},"requestUrl":"/m/hq/s/ORMP/tweets","defaultTab":"tweets","newsList":[{"id":"2585105161","title":"Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2585105161","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585105161?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:08","pubTimestamp":1763723323,"startTime":"0","endTime":"0","summary":"Investors appear disappointed with Oramed Pharmaceuticals Inc.'s ( NASDAQ:ORMP ) recent earnings, despite the decent...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ormp/oramed-pharmaceuticals/news/oramed-pharmaceuticals-nasdaqormp-profits-may-be-overstating","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ormp/oramed-pharmaceuticals/news/oramed-pharmaceuticals-nasdaqormp-profits-may-be-overstating","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORMP",".IXIC"],"gpt_icon":0},{"id":"2584629282","title":"BRIEF-Oramed Reports Fiscal Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629282","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629282?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:02","pubTimestamp":1763388176,"startTime":"0","endTime":"0","summary":"BRIEF-Oramed Reports Fiscal Third Quarter 2025 Financial ResultsOramed Pharmaceuticals Inc ORMP.O:ORAMED REPORTS FISCAL THIRD QUARTER 2025 FINANCIAL RESULTSSource text: ID:nPnb1nV5MaFurther company coverage: ORMP.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA2XSQWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2584629152","title":"Oramed Pharmaceuticals Q3 EPS USD 1.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629152?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:58","pubTimestamp":1763387909,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nPLX8B18E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2584629988","title":"Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629988","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629988?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:58","pubTimestamp":1763387904,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $(0.08) by 1675 percent. This is a 672.73 percent increase over losses of $(0.22) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48897165/reported-november-13-2025-oramed-pharmaceuticals-q3-eps-1-26-beats-0-08-estimate-sales-2-000m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP"],"gpt_icon":0},{"id":"2584296886","title":"Oramed Pharmaceuticals reports $65 million net income for nine months ended September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584296886","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584296886?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:56","pubTimestamp":1763387811,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. reported unaudited financial results for the nine months ended September 30, 2025. The company recorded a pre-tax net income of $65.0 million, compared to a net loss of $6.1 million for the same period last year. Basic earnings per share were $1.30 and diluted earnings per share were $1.26. Total assets rose by 42% year-over-year, from $155.3 million to $220.5 million. Research and development expenses decreased from $4.9 million to $4.4 million, while general and administrative expenses increased from $4.3 million to $5.0 million. During the period, Oramed completed a full $100 million principal repayment from Scilex and reported substantial unrealized gains from its equity holdings in Alpha Tau Medical Ltd. and other investments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4PSslg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4082","DRTS","BK4007"],"gpt_icon":0},{"id":"2584296486","title":"Oramed declares dividend distribution of common stock purchase rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2584296486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584296486?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:55","pubTimestamp":1763387719,"startTime":"0","endTime":"0","summary":"Oramed (ORMP) has unanimously adopted a Rights Agreement dated November 17 by and between the company and its rights agent, and declared a dividend...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oramed-declares-dividend-distribution-of-common-stock-purchase-rights-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oramed-declares-dividend-distribution-of-common-stock-purchase-rights-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2584629539","title":"Oramed Pharmaceuticals Inc. announces stock purchase right dividend of one right per share with $10.00 exercise price","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629539","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629539?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:50","pubTimestamp":1763387412,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. has announced a dividend distribution of one common stock purchase right for each outstanding share of its common stock. This new dividend is in the form of stock purchase rights, with each right allowing shareholders to buy one share at a purchase price of $10.00 if certain conditions are met. No dividend was distributed the previous year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire  on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL8w1y5b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2584629587","title":"Press Release: ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629587","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629587?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:50","pubTimestamp":1763387400,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc.  announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 , by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right  on each outstanding share of its common stock, par value $0.012 per share , of the Company.  The Rights are designed to assure that all stockholders of the Company receive fair and equal treatment in the event of a hostile takeover of the Company, to guard against tactics designed to gain control of the Company without paying all stockholders a fair price, and to enhance the Board's ability to negotiate with any prospective acquiror.The dividend distribution will be payable on November 27, 2025, to stockholders of record as of the close of business on November 27, 2025.  The Rights will expire three years after the date of adoption of the Rights Plan ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4555","ORMP","BK4585","INC","BK4007","BK4604","BK4099","BK4588","TM"],"gpt_icon":0},{"id":"2583850939","title":"Lifeward Ltd. posts Q3 revenue of $6.2 million and reports 16% decrease in cash burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2583850939","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583850939?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:16","pubTimestamp":1763126188,"startTime":"0","endTime":"0","summary":"Lifeward Ltd. reported revenue of $6.2 million for the third quarter of 2025, up 1.0% from $6.1 million in the third quarter of 2024 and an 8.0% increase from $5.7 million in the second quarter of 2025. Revenue from the sale of traditional products and services, including ReWalk Personal exoskeletons and the MyoCycle FES bike, was $3.1 million, representing a 24.0% increase year-over-year, attributed to higher Medicare-related sales. The company recorded a net loss of $3.6 million, or $0.41 per share, compared to a net loss of $4.0 million, or $0.45 per share, in the same period last year. Cash used in operations decreased by 16.0% to $3.8 million from $4.5 million in the prior year quarter. As of September 30, 2025, Lifeward had $2.0 million in unrestricted cash and no debt. After the quarter ended, Lifeward entered into a $3.0 million loan agreement with Oramed Ltd. The company reaffirmed its full-year 2025 revenue guidance of $24 to $26 million and projected a non-GAAP net loss betw","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3ZBWjG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4604","BK4007","LFWD","ORMP"],"gpt_icon":0},{"id":"2580225033","title":"Oramed Pharmaceuticals Inc  expected to post a loss of 19 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580225033","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580225033?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:39","pubTimestamp":1762205944,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post a loss of19cents a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to  show a rise in quarterly revenue when it reports  res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF2CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2577594988","title":"Oramed Pharmaceuticals  - on Oct 20, Enters Share Repurchase Agreement With Htit Biotech - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577594988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577594988?lang=en_us&edition=fundamental","pubTime":"2025-10-24 18:03","pubTimestamp":1761300205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W51LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2577594939","title":"Oramed Pharmaceuticals Inc - Purchase Price Set at $2.23 per Share, Total $2.58 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577594939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577594939?lang=en_us&edition=fundamental","pubTime":"2025-10-24 18:03","pubTimestamp":1761300205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W51LA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2577302628","title":"Oramed Pharmaceuticals Inc - Launches New U.S. Trial for Oral Insulin Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2577302628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577302628?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:55","pubTimestamp":1761224145,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nFWN3W40GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2577641302","title":"Oramed Pharmaceuticals Outlines Independent Advancement of Oral Insulin Program, Launch of New U.S. Trial, and Continued Diversification Through Strategic Biomedical Investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2577641302","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577641302?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:55","pubTimestamp":1761224124,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Outlines Independent Advancement of Oral Insulin Program, Launch of New U.S. Trial, and Continued Diversification Through Strategic Biomedical Investments. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire  on October 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL2BNXsb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2573670213","title":"Oramed Pharmaceuticals Sells 3.13M Scilex Warrants for $13M; Option Remains for Additional 3.37M Warrants at $14M","url":"https://stock-news.laohu8.com/highlight/detail?id=2573670213","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573670213?lang=en_us&edition=fundamental","pubTime":"2025-10-06 21:28","pubTimestamp":1759757337,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. has entered into an agreement with Scilex Holding Company for the repurchase of warrants to purchase a total of 6,500,000 shares of Scilex common stock at an exercise price of $0.01 per share. On September 30, 2025, Scilex completed the first tranche by repurchasing warrants for 3,130,000 shares for $13,000,000. Scilex retains the option to repurchase the remaining 3,370,000 warrants for $14,000,000 on or before December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 0","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL80cvVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP","SCLX"],"gpt_icon":0},{"id":"2572863534","title":"Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2572863534","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572863534?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:00","pubTimestamp":1759323600,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Oct.  01, 2025  (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/01/3159560/0/en/Scilex-Holding-Company-Announces-the-Completion-of-the-First-Tranche-of-the-Oramed-Pharmaceuticals-Inc-Warrant-Repurchase.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP","SCLX"],"gpt_icon":0},{"id":"2561041526","title":"Oramed Pharmaceuticals Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2561041526","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561041526?lang=en_us&edition=fundamental","pubTime":"2025-08-22 04:06","pubTimestamp":1755806816,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. held its 2025 Annual Meeting of Stockholders on August 19, 2025. During the meeting, stockholders re-elected directors including Dr. Daniel Aghion, Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yehuda Reznick, and Leonard Sank. Additionally, an amendment to the company's Amended and Restated 2019 Stock Incentive Plan was approved, increasing the number of shares authorized for issuance by 2,000,000 to a total of 9,500,000 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nNDL3Mj6kn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2558577918","title":"Oramed Pharmaceuticals Inc  expected to post a loss of 19 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558577918","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558577918?lang=en_us&edition=fundamental","pubTime":"2025-08-09 05:41","pubTimestamp":1754689266,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post a loss of19cents a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to  show no change in quarterly revenue when it reports  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U03NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP"],"gpt_icon":0},{"id":"2553248926","title":"BRIEF-Oramed Pharmaceuticals Enters Option Agreement With Scilex For Warrant Repurchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2553248926","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553248926?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:39","pubTimestamp":1753274342,"startTime":"0","endTime":"0","summary":"BRIEF-Oramed Pharmaceuticals Enters Option Agreement With Scilex For Warrant Repurchase July 23  - Oramed Pharmaceuticals Inc ORMP.O:ORAMED PHARMACEUTICALS INC - ENTERS OPTION AGREEMENT WITH SCILEX FOR WARRANT REPURCHASE - SEC FILINGORAMED PHARMACEUTICALS INC - REPURCHASE OF WARRANTS FOR $27 MILLION IN TWO TRANCHES - SEC FILINGSource text: [ID:n0001213900-25-066819]Further company coverage: ORMP.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nFWN3TK16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2553625248","title":"Oramed Pharmaceuticals Inc - Enters Option Agreement With Scilex for Warrant Repurchase - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2553625248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553625248?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:37","pubTimestamp":1753274246,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nFWN3TK16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oramed.com","stockEarnings":[{"period":"1week","weight":0.0662},{"period":"1month","weight":0.2719},{"period":"3month","weight":0.1934},{"period":"6month","weight":0.3679},{"period":"1year","weight":0.1554},{"period":"ytd","weight":0.1983}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.004413},{"month":2,"riseRate":0.5,"avgChangeRate":-0.020726},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.013462},{"month":4,"riseRate":0.769231,"avgChangeRate":0.017276},{"month":5,"riseRate":0.538462,"avgChangeRate":0.041552},{"month":6,"riseRate":0.384615,"avgChangeRate":0.018782},{"month":7,"riseRate":0.461538,"avgChangeRate":0.04461},{"month":8,"riseRate":0.384615,"avgChangeRate":0.00834},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.048853},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.028699},{"month":11,"riseRate":0.538462,"avgChangeRate":0.137309},{"month":12,"riseRate":0.461538,"avgChangeRate":0.052683}],"exchange":"NASDAQ","name":"Oramed Pharmaceuticals","nameEN":"Oramed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oramed Pharmaceuticals,ORMP,Oramed Pharmaceuticals股票,Oramed Pharmaceuticals股票老虎,Oramed Pharmaceuticals股票老虎国际,Oramed Pharmaceuticals行情,Oramed Pharmaceuticals股票行情,Oramed Pharmaceuticals股价,Oramed Pharmaceuticals股市,Oramed Pharmaceuticals股票价格,Oramed Pharmaceuticals股票交易,Oramed Pharmaceuticals股票购买,Oramed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}